Targeted TLR9-activation/STAT3-blocking abrogates immunosuppressive functions of myeloid-derived suppressor cells from late-stage prostate cancer patients
Citation:
Journal for ImmunoTherapy of Cancer
2014
2(Suppl 3):P104